INTRODUCTION
The signal-transduction cascade known as the phosphoinositide pathway is activated by a wide variety of hormones and growth factors [1, 2] . The receptors for these agonists are either coupled to G-proteins, like the thromboxane A2-receptor and the muscarinic receptor [3, 4] , or contain an intrinsic tyrosine kinase, like the epidermal growth factor (EGF) receptor and plateletderived growth factor (PDGF) receptor [5] . It has been shown that different isoforms of phospholipase C (PLC) are implicated in each pathway; for example, PLC fl,1 is regulated by Gq [6] , whereas a cytosolic isoform called PLCy1 is phosphorylated and activated by several tyrosine-kinase-containing receptors [7] . Recently, the receptor for thrombin has been cloned; it belongs to the seven-transmembrane-domain receptor family, suggesting its coupling to G-proteins [8] . Moreover, the activation of PLC in thrombin-stimulated human platelets has been demonstrated to occur through a G-protein [9] . However, it is now well established that thrombin also induces specific tyrosine phosphorylation of several proteins in platelets [10, 11] . In this respect, it is noteworthy that tyrosine phosphorylation of some of these proteins may correlate with 5-hydroxytryptamine (serotonin) secretion and aggregation [12] , cyclic AMP elevation [13] or increased phosphoinositide turnover [14] . The tyrosine kinase(s) responsible for these specific phosphorylations, as well as its (their) regulation, have not been elucidated so far. One can suggest that non-receptor tyrosine kinases of the src family, which are abundant in platelets [15] , could play this role. On the other hand, we and others have reported a relationship between receptor and non-receptor tyrosine kinases and the phosphoinositide metabolism [16, 17] . Indeed, activation of was partially blocked. Inositol phosphate production was also inhibited by about 40 % when tyrphostin-treated platelets were stimulated with thrombin. In addition, we show by Western-blot analysis that PLCyl, as well as the regulatory subunit (p85) of the PtdIns 3-kinase, were present in the anti-phosphotyrosine immunoprecipitate isolated from thrombin-stimulated platelets. Furthermore, tyrphostin treatment clearly decreased the PLCyl and p85 contents in such an anti-phosphotyrosine immunoprecipitate. Our results provide the first evidence for a direct or indirect regulation of PtdIns(3,4)P2 accumulation and PLCyl activity by tyrosine phosphorylation during thrombin stimulation of human platelets.
Ptdlns 3-kinase or PLCyl has been shown to involve tyrosine kinase activities [7, 18] , and some studies suggest that PtdIns 4-kinase and/or PtdIns4P 5-kinase may be associated with and regulated by the EGF receptor [17, 19] . Therefore, it was decided to investigate the implication of tyrosine kinase activities in the different aspects of the thrombin-dependent activation of phosphoinositide metabolism in human platelets.
For this purpose we have used tyrphostin AG-213 as tyrosine kinase inhibitor [20] , and we have shown firstly that physiological responses of platelets, such as aggregation and 5-hydroxytryptamine secretion, were markedly affected by tyrphostin treatment. Secondly, we have observed that PtdIns(3,4)P2 and phosphatidic acid (PtdOH) synthesis, which is classically observed during thrombin activation of platelets, were significantly inhibited by tyrphostin treatment. Accumulation of PtdIns(3,4)P2 in platelets has been reported to implicate the binding of fibrinogen to the integrin GpIIb/IIIa [21] , which is also able to regulate specific tyrosine phosphorylations in platelets [22] . On the other hand, the partial inhibition of both PtdOH synthesis and inositol phosphate formation observed in the presence of tyrphostin suggested the participation of a PLCy isoform in thrombin-stimulated platelets. We have confirmed the relationship between PLC as well as Ptdlns 3- 
Measurement of aggregation and 5-hydroxytryptamine secretion
Aggregation was monitored by turbidometry using a Chronolog aggregometer with stirring at 600 rev./min (5 x 108 cells/ml). 5-Hydroxytryptamine secretion was performed as previously described [24] ; briefly, 5-hydroxy[14C]tryptamine (Amersham International)-labelled platelets (2 x 101 cells/ml) were preincubated with or without tyrphostin and stimulated with increasing concentrations of thrombin for 5 min. Incubation was stopped by addition of 10 mM EDTA, cooling on ice and centrifugation. 5-Hydroxy[14C]tryptamine released from platelet dense granules was determined by liquid-scintillation counting.
Lactate dehydrogenase measurements were used to check the tyrphostin cytotoxicity and performed as described in [25] .
Lipid extraction and analysis
Lipids were extracted, deacylated by methylamine treatment, identified and quantified by an h.p.l.c. technique on a Whatman Partisphere SAX column as previously described [26] .
Assay of PLC activity on exogenous substrate PLC activity present in anti-phosphotyrosine immunoprecipitates was detected with Ptd[3H]Ins(4,5)P2 (Amersham International) as exogenous substrate. The reaction was performed at 37°C during 10 min as previously described [27] .
Inositol phosphate measurement
The upper phases obtained from the lipid extraction of myo-[3H]inositol-labelled platelets (2 x 109 cells/ml) were neutralized with NaOH, diluted with water to 5 ml and applied to 1 ml columns of AG1-X8 anion-exchange resin (Bio-Rad, Richmond, CA, U.S.A.). Sequential elutions were performed as described by Berridge et al. [28] ; however, after elution of glycerophosphoinositol, InsP1, InsP2 and InsPJ were eluted together with 0.1 M formic acid/1.0 M ammonium formate. lmmunopurfication Reactions (6 x 109 cells/ml) were stopped by addition of 1 vol. of buffer B containing 40 mM Tris/HCl (pH 7.4), 100 mM NaCl, 100 mM NaF, 10 mM EDTA, 40 mM Na4P207, 2 mM sodium orthovanadate, 2 ,ug/ml aprotinin, 2 sg/ml leupeptin, 200 ,ug/ml phenylmethanesulphonyl fluoride and 2% digitonin, followed by sonication for 5 s at 20 kHz (Ultrasonic Cell Disruptor) at room temperature. After 10 min on ice, sonication (5 s, 20 kHz) and centrifugation (12000 g, 5 min at 4°C), the soluble fraction was collected and incubated for 150 min at 4°C with an antiphosphotyrosine antibody coupled to agarose (Oncogene Science). After one washing step in buffer B diluted in 1 vol. of distilled water and three washing steps in 10 mM Tris/HCl (pH 7.4) containing 100 mM NaCl, 1 jug/ml leupeptin, 1 ,ug/ml aprotinin and 100 ,ug/ml phenylmethanesulphonyl fluoride, the phosphotyrosyl-proteins were then eluted in 10 mM Tris/HCl (pH 7.4) containing 100 mM NaCl and 10 mM phenyl phosphate as described previously [17] .
Gel electrophoresis and immunoblotting Phosphotyrosyl-proteins obtained from immunopurification were resuspended in sample buffer [100 mM Tris/HCl (pH 6.8), 15 % (v/v) glycerol, 25 mM dithiothreitol, 3 % SDS], and proteins were separated by SDS/PAGE in a 7.5 % gel. Proteins were blotted on to nitrocellulose as described previously [29] . Immunodetection was performed with a polyclonal antibody to the p85 regulatory subunit of the PtdIns 3-kinase (dilution 1/500; UBI) or a monoclonal antibody to PLCy1 (dilution 1/3000; Zymed Laboratories) and anti-rabbit or anti-mouse antibodies conjugated to alkaline phosphatase as secondary antibodies. 5-Bromo-4-chloro-3-indolyl phosphate was used as substrate for alkaline phosphatase.
RESULTS

Inhibition of thrombin-induced platelet aggregation and 5-hydroxytryptamine release by tyrphostin treatment
When platelets were stimulated with 0.3 or 0.7 i.u. of thrombin/ml, typical aggregation profiles were observed (Figures la and lb respectively). Treatment with tyrphostin fully inhibited the aggregation obtained at 0.3 i.u./ml (Figure la) , whereas a partial inhibition was observed at 0.7 i.u. of thrombin/ml ( Figure  lb) .
As indicated in Figure 2 , 5-hydroxytryptamine release from dense granules was also fully inhibited by tyrphostin at 0.1 i.u. of thrombin/ml, and partially inhibited at higher thrombin concentration. Furthermore, we have checked that tyrphostin treatment had no lytic effect. Indeed, lactate dehydrogenase activity in the supernatant of tyrphostin-treated platelets represented 2.5 + 0.3 % (n = 2) of the total activity measured in platelet homogenate and was similar to that measured in the supernatant of control cells.
These inhibitory effects of tyrphostin on the physiological As shown in Figure 3 , when metabolically 32P-labelled platelets were stimulated for 5 min by increasing concentrations of thrombin, we observed a dose-dependent appearance of [32P]PtdOH. It is admitted that in platelets the synthesis of PtdOH results mainly from the activation of a Ptdlns-specific PLC producing diacylglycerol (DAG), which is subsequently phosphorylated to PtdOH by a DAG kinase. As shown in Figure 3 On the other hand, as we previously reported [26] , Figure 4 shows a dose-dependent production of PtdIns (3,4) [32] . Therefore our results suggest regulation of a PLC as well as PtdIns 3-kinase and/or PtdIns3P 4-kinase [33] by tyrosine kinases in human platelets.
Presence of PLCy1 and p85 in anti-phosphotyrosine immunoprecipitate In order to confirm a relationship between tyrosine phosphorylation and PLC or Ptdlns 3-kinase, we have performed immunopurification of phosphotyrosyl-proteins from a digitonin-soluble fraction of platelets and probed them with antiPLCyl and anti-p85 antibodies. As indicated in Figure 5 , when anti-phosphotyrosine immunoprecipitate from resting platelets (lane 1) was probed with anti-PLCyl antibody, we could detect a single protein with an apparent molecular mass of 145 kDa, corresponding to the expected size of PLCyl. An increase in PLCyl content was observed in the anti-phosphotyrosine immunoprecipitate isolated from thrombin-activated platelets ( Figure 5, land 2) . Finally, PLCyl was hardly detectable when platelets were pretreated with tyrphostin (lane 3). In parallel, PLC activity was measured by an assay in vitro in the anti-phosphotyrosine immunoprecipitate from resting or thrombin-activated platelets. A weak PLC activity could be detected in control (100 + 30 fmol of [3H]InsP3/min produced; mean+ S.E.M., n = 3), whereas an increase (270+100 fmol/min of [3H]InsP3 produced; mean + S.E.M., n = 3) was observed upon thrombin stimulation. In the anti-phosphotyrosine immunoprecipitate from resting platelets ( Figure 6 , lane 1) we also detected by Western blotting, using an anti-p85 antibody, a single protein band of 85 kDa corresponding to the described mass of the regulatory subunit (p85) of Ptdlns 3-kinase. A clear increase in the p85 content was observed in the immunoprecipitate from thrombin-activated platelets ( Figure 6 , lane 2), and this increase was significantly decreased by tyrphostin treatment (Figure 6, lane 3) .
DISCUSSION
Our present data argue in favour of a role of tyrosine phosphorylation in several aspects of platelet activation by thrombin. We demonstrate that thrombin-induced platelet aggregation as well as 5-hydroxytryptamine secretion are strongly inhibited by tyrphostin treatment. However, although significant, this inhibition is clearly decreased at high thrombin concentration, suggesting that several signals may converge to regulate these processes. These observations already reported [30] indicate that, besides specific tyrosine phosphorylations, downstream biochemical reactions classically observed during thrombin activation of platelets may be affected by tyrosine kinase inhibitors. However, the precise regulatory role of these tyrosine phosphorylations is still unclear. In other models, PLCy1 and Ptdlns 3-kinase regulatory subunit, two proteins participating in phosphoinositide metabolism, are tyrosine-phosphorylated and activated by several tyrosine-kinase-containing receptors [7, 18] .
Although it is well established that PLC activation in thrombinstimulated platelets is largely dependent on G-proteins [9] , we have demonstrated here that tyrphostin partially blocks the PtdOH synthesis and the inositol phosphate production induced by thrombin stimulation. These observations suggest a contribution of tyrosine phosphorylation in PLC activation upon thrombin stimulation. The discrepancy observed between our present results and those previously published [30] may be due to the fact that we have used for the present study higher concentrations of thrombin for a longer stimulation time, and may emphasize the existence of a G-protein-dependent and a Gprotein-independent pathway by which thrombin may activate PLC isoforms in platelets. This could also explain the lack of parallelism between the inhibition of PLC and of aggregation/ secretion. On the other hand, we have shown that PtdIns (3, 4) P2 accumulation is significantly inhibited by tyrphostin in thrombin-stimulated platelets. This inhibition seems to be parallel to the inhibition of the thrombin-dependent aggregation. Our data suggest that Ptdlns 3-kinase and/or PtdIns3P 4-kinase may be directly or indirectly regulated via tyrosine phosphorylation in platelets. In this respect, it is noteworthy that PtdIns(3,4)P2 synthesis and tyrosine phosphorylation of a pool of proteins have been shown to be dependent on fibrinogen binding to GpIIb/IIIa, since they are inhibited by the fibrinogen-bindingsite analogue RGDS [21, 22] .
Finally, we confirm the relationship between tyrosine phosphorylations and phosphoinositide metabolism by demonstrating the presence of both PLCy1 and the regulatory subunit of Ptdlns 3-kinase (p85) in the anti-phosphotyrosine immunoprecipitate obtained from thrombin-activated platelets. The immunodetection of PLCyl and p85 in such an immunoprecipitate does not obligatorily mean a direct phosphorylation detected a direct tyrosine phosphorylation of PLCy1 or p85 in our samples (results not shown). However, with respect to the existence of SH2 and SH3 domains in these molecules [34] , one can expect the formation of signalling complexes which may include both tyrosine-phosphorylated and non-tyrosinephosphorylated proteins. Since we have solubilized the platelets with the mild detergent digitonin, such associations of proteins may be relatively well conserved and may explain the presence of non-tyrosine-phosphorylated proteins in the anti-phosphotyrosine immunoprecipitate. In this respect, it is noteworthy that an association between PLCy1, p21ra8-GTPase activating protein (ras GAP) and rapIB in thrombin-activated human platelets was recently reported [35] . The latter authors suggested that these associations may allow the interaction ofPLCyl with its substrate located in the membrane. They further showed that, upon thrombin stimulation, PLCy1 was indeed phosphorylated, but not on a tyrosine residue, by contrast with ras GAP, which was tyrosine-phosphorylated. Furthermore, an association of ras GAP with three src-related tyrosine kinases (fyn, lyn and yes) has been reported in thrombin-activated human platelets [36] . With respect to the presence of SH2 domains in most of these proteins, one can expect that the formation of signalling complexes may be under control of tyrosine phosphorylations.
Altogether these results suggest that non-receptor tyrosine kinases, as well as the formation of signalling complexes including PLCy1, ras GAP, rapIB and possibly src-related proteins, may play an important role in signalling via the thrombin receptor. The partial inhibition by tyrphostin of PLC activation that we have observed may be due to the lack of formation of such a complex; this is consistent with the fact that PLCyl is weakly present in the anti-phosphotyrosine immunoprecipitate from thrombin-stimulated tyrphostin-treated platelets.
On the other hand, p85 may also participate in this complex, since an association of Ptdlns 3-kinase with p2lra8 has been shown in Ha-ras-transformed epithelial cells [37] . It is also noteworthy that Torti et al. [38] have recently shown an association of a small G-protein with GpIIb/IIIa. Furthermore, the inhibition ofthrombin-dependent PtdIns(3,4)P2 accumulation by RGDS that we have previously reported [21] and the inhibition of its synthesis by tyrphostin reported here correlated with the inhibition of aggregation. However, recent reports from King et al. [39] and Sorisky et al. [401 demonstrated the role of both protein kinase C and Ca2+ in thrombin-dependent Ptdlns (3, 4) P, accumulation, suggesting that this synthesis involves different intracellular signals to be total.
In conclusion, our data strongly argue for the existence of a tyrosine-phosphorylation-dependent pathway to activate PLC in human platelets, probably by involving a PLCy1 isoform and the formation of multienzymic complexes. Our results also suggest a relationship between the synthesis of a 3-phosphorylated inositol lipid [Ptdlns(3,4)P2] and tyrosine kinase activities in thrombinstimulated platelets, possibly via GpIIb/IIIa. Further investigations concerning the direct or indirect role of tyrosine kinases in the regulation of PLC and Ptdlns 3-kinase in human platelets are now in progress.
